Skip to main content

Table 1 Demographics and clinical characteristics of the wrist fracture patients and the control group

From: Is health-related quality of life associated with the risk of low-energy wrist fracture: a case-control study

  Wrist fracture Controls p*
  n = 181 n = 181  
Demographics    
Age (years) 66.9 (9.9) 66.8 (9.1) 0.885
Females 161 (89) 161 (89) 1.000
BMI (kg/m2) 25.4 (4.3) 26.6 (4.3) 0.009
Menarche (years) 13.9 (1.5) 13.6 (1.4) 0.046
Menopause (years) 48.9 (4.4) 49.5 (4.1) 0.228
Education    0.029
< 10 years 62 (37) 73 (40)  
11–13 years 70 (42) 52 (29)  
> 13 years 36 (21) 55 (31)  
Co-habiting 95 (53) 118 (66) 0.014
Regular exercise** 134 (74) 132 (73) 0.812
Current smoker 29 (16) 23 (13) 0.380
Clinical characteristics
Heart diseases 56 (31) 62 (34) 0.501
Pulmonary diseases 24 (13) 13 (7) 0.056
Neurological diseases 14 (8) 17 (9) 0.573
Endocrine disorders 14 (8) 20 (11) 0.280
Gastrointestinal disorders 12 (7) 22 (12) 0.072
Urogenital disorders 5 (3) 1 (0.5) 0.100
Inflammatory joint and connective tissue disorders 43 (24) 50 (28) 0.400
Cancer 18 (10) 19 (11) 0.862
Mental disorders 7 (4) 11 (6) 0.333
Mean total score co-morbidity (range 0–6) 1.1 (1.1) 1.1 (1.1) 0.259
Current glucocorticoid treatment 12 (7) 3 (2) 0.044
Current calcium and/or vitamin D treatment 40 (22) 43 (24) 0.708
Current ART 26 (14) 11 (6) 0.009
Osteoporosis*** 60 (33) 31 (17) < 0.001
≥1 fall in the previous year 75 (47) 54 (37) 0.089
Previous fracture(s) 97 (54) 82 (46) 0.153
  1. Continuous variables are presented as mean (SD) and group variables as numbers and (%).
  2. * Chi-squared analysis was used to compare categorical data, and an independent t test was used to compare continuous variables.
  3. Bold p values indicate significant differences between the groups.
  4. ** Exercise more than 30 minutes three times a week.
  5. *** Osteoporosis at the total hip or lumbar spine L2-L4 or both.
  6. BMI, body mass index; ART, anti-resorptive treatment, a specific osteoporosis treatment comprising oestrogens, biphosphonates, or selective oestrogen-receptor modulators.